Novel Influenza Polymerase PB2 Inhibitors for the Treatment of Influenza A Infection

Overview

Journal Bioorg Med Chem Lett

Specialty Biochemistry

Date 2019 Sep 9

PMID 31493987

Citations 3

Authors

Hongwang Zhang

Longhu Zhou

Sarah Amichai

Keivan Zandi

Bryan Cox

Raymond Schinazi

Franck Amblard

Affiliations

Soon will be listed here.

Abstract

Exploration of the chemical space of known influenza polymerase PB2 inhibitor Pimodivir, was performed by our group. We synthesized and identified compounds 16a and 16b, two novel thienopyrimidine derivatives displaying anti-influenza A activity in the single digit nanomolar range in cell culture. Binding of these unique compounds in the influenza polymerase PB2 pocket was also determined using molecular modeling.

Citing Articles

Synthesis of 4'-Substituted Carbocyclic Uracil Derivatives and Their Monophosphate Prodrugs as Potential Antiviral Agents.

Biteau N, Amichai S, Azadi N, De R, Downs-Bowen J, LeCher J Viruses. 2023; 15(2).

PMID: 36851758 PMC: 9962574. DOI: 10.3390/v15020544.

Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins.

Hou L, Zhang Y, Ju H, Cherukupalli S, Jia R, Zhang J Acta Pharm Sin B. 2022; 12(4):1805-1824.

PMID: 35847499 PMC: 9279641. DOI: 10.1016/j.apsb.2021.11.018.

Thienopyrimidine: A Promising Scaffold to Access Anti-Infective Agents.

Lagardere P, Fersing C, Masurier N, Lisowski V Pharmaceuticals (Basel). 2022; 15(1).

PMID: 35056092 PMC: 8780093. DOI: 10.3390/ph15010035.

References

Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M . Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018; 8(1):9633. PMC: 6018108. DOI: 10.1038/s41598-018-27890-4. View

Shaw M . The Next Wave of Influenza Drugs. ACS Infect Dis. 2017; 3(10):691-694. DOI: 10.1021/acsinfecdis.7b00142. View

Sherman W, Day T, Jacobson M, Friesner R, Farid R . Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem. 2006; 49(2):534-53. DOI: 10.1021/jm050540c. View

Trevejo J, Asmal M, Vingerhoets J, Polo R, Robertson S, Jiang Y . Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study. Antivir Ther. 2017; 23(4):335-344. DOI: 10.3851/IMP3212. View

Bright R, Medina M, Xu X, Perez-Oronoz G, Wallis T, Davis X . Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005; 366(9492):1175-81. DOI: 10.1016/S0140-6736(05)67338-2. View

Harding A, Heaton N . Efforts to Improve the Seasonal Influenza Vaccine. Vaccines (Basel). 2018; 6(2). PMC: 6027170. DOI: 10.3390/vaccines6020019. View

Yuan S, Wen L, Zhou J . Inhibitors of Influenza A Virus Polymerase. ACS Infect Dis. 2018; 4(3):218-223. DOI: 10.1021/acsinfecdis.7b00265. View

Hurt A, Ernest J, Deng Y, Iannello P, Besselaar T, Birch C . Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 2009; 83(1):90-3. DOI: 10.1016/j.antiviral.2009.03.003. View

Bandarage U, Clark M, Perola E, Gao H, Jacobs M, Tsai A . Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza. ACS Med Chem Lett. 2017; 8(2):261-265. PMC: 5304303. DOI: 10.1021/acsmedchemlett.6b00487. View

10.

Finberg R, Lanno R, Anderson D, Fleischhackl R, van Duijnhoven W, Kauffman R . Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial. J Infect Dis. 2018; 219(7):1026-1034. DOI: 10.1093/infdis/jiy547. View

11.

Clark M, Ledeboer M, Davies I, Byrn R, Jones S, Perola E . Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem. 2014; 57(15):6668-78. DOI: 10.1021/jm5007275. View

12.

Farmer L, Clark M, Boyd M, Perola E, Jones S, Tsai A . Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2. ACS Med Chem Lett. 2017; 8(2):256-260. PMC: 5304291. DOI: 10.1021/acsmedchemlett.6b00486. View

13.

Hayden F, Sugaya N, Hirotsu N, Lee N, de Jong M, Hurt A . Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018; 379(10):913-923. DOI: 10.1056/NEJMoa1716197. View

14.

Hurt A, Hardie K, Wilson N, Deng Y, Osbourn M, Gehrig N . Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med. 2011; 365(26):2541-2. DOI: 10.1056/NEJMc1111078. View

15.

Sherman W, Beard H, Farid R . Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des. 2006; 67(1):83-4. DOI: 10.1111/j.1747-0285.2005.00327.x. View

16.

Pflug A, Gaudon S, Resa-Infante P, Lethier M, Reich S, Schulze W . Capped RNA primer binding to influenza polymerase and implications for the mechanism of cap-binding inhibitors. Nucleic Acids Res. 2017; 46(2):956-971. PMC: 5778463. DOI: 10.1093/nar/gkx1210. View